newsfilter
← Latest News
GlobeNewswire·

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

  • ORIC Pharmaceuticals will present three posters at the ESMO Congress 2026 in Madrid, Spain, scheduled for October 23-27, 2026.
  • Enozertinib (ORIC-114) data from a Phase 1b trial in treatment-naive metastatic NSCLC with EGFR atypical mutations will be presented on October 26, 2026.
  • The Himalayas-1 Phase 3 study design for rinzimetostat combined with darolutamide in mCRPC patients previously treated with abiraterone will be presented on October 23, 2026.
  • An ePoster will highlight preclinical & mechanistic proof-of-concept data showing rinzimetostat enhances AR signaling & restricts lineage plasticity in mCRPC.
  • Full abstracts for all three presentations will be available on the ESMO Congress website starting October 19, 2026.
  • ORIC Pharmaceuticals is a clinical stage company with offices in South San Francisco & San Diego, California.